Results from Abbott’s PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery DiseaseSAN FRANCISCO - Abbott (NYSE: ABT) today announced primary results from its groundbreaking PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) clinical trial. PROSPECT is the first prospective natural history study to evaluate the role of vulnerable plaque in unexpected heart attacks and the natural progression of coronary artery disease. Results were presented today during the late-breaking clinical trials session by Gregg W. Stone, M.D., professor of medicine at Columbia University Medical Center, during the 2009 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting. Astellas Pharma Europe Announces Winners of the Changing Tomorrow 2009 AwardsSTAINES, England - Astellas Pharma Europe Ltd., the European subsidiary of Tokyo-based Astellas Pharma Inc., one of the world’s top 20 pharmaceutical companies, has today announced the launch of the Astellas Changing Tomorrow Charity Awards. The charity award funding programme is designed to award organisations that help citizens of all communities realise their full potential and enhance their quality of life - both today and in the future. Janssen-Cilag’s STELARA(R) (Black Triangle Drug) (ustekinumab) Approved by NICE for the Treatment of Moderate to Severe Plaque PsoriasisHIGH WYCOMBE, England - - For Medical Media Only - Not for Republic of Ireland Media STELARA (ustekinumab) has today been approved by the National Institute for Health and Clinical Excellence (NICE) as a treatment option for adults with moderate to severe plaque psoriasis,(1) a notoriously difficult-to-treat skin condition for which many patients report feeling dissatisfied and frustrated with existing treatment options.(2) Cancer Protection Supported by UV ExposureVELDHOVEN, The Netherlands - Regular, moderate UV exposure contributes to protection against breast, prostrate and colorectal cancer (colon and rectal cancer) as well as non Hodgkin’s lymphoma (one of two forms of lymph node cancers). A team of Dutch scientists led by Han von der Rhee from the Haager clinic group “Hagaziekenhuis” and the University of Rotterdam came to this conclusion in a study that has now been published in the specialist magazine “European Journal of Cancer Prevention”. In their article, von der Rhee and his colleagues also refer to the fact that the public perception of the effects of UV exposure is lagging behind the current scientific knowledge. “The work of the Dutch researchers shows once again that UV exposure has a positive influence on human health. The potential risks connected with overexposure are well known to the general public. On the other hand the health promoting aspects of moderate UV exposure outdoors or under a sunbed regularly receive too little exposure in information available to the public”, explains Ad Brand from Sunlight Research Forum (SRF). MS Society Statement - Assisted Suicide GuidanceLONDON - LONDON, September 23 /PRNewswire/ – The MS Society has responded to today’s (Wednesday’s) clarification on assisted suicide in England and Wales by the Director of Public Prosecutions (DPP). OneDotOneLife.org - Saving the Lives of More Than 2 Million ChildrenPORTO, Portugal - As of today, 23 September 2009, the site will be online www.onedotonelife.org, an innovative project on the Internet which combines social solidarity and digital art. Capecitabine Added to Standard Treatment Given Before Surgery Helps to Eradicate Tumours in Patients With Early Breast CancerBERLIN - - The Austrian Breast and Colorectal Cancer Study Group Present Data Which Highlight Benefits of Adding capecitabine to epirubicin and docetaxel in the Neoadjuvant Setting NeuroTherm is Awarded US Patent for Multi-lesion Radiofrequency GeneratorWILMINGTON, Massachusetts - NeuroTherm is pleased to be recognized by the United States Patent Office as the first company worldwide to develop and release a multiple output radiofrequency generator used in the treatment of chronic pain, ref. US Patent No. 7,574,257. InspireMD Announces the Enrollment of the 1st Patient in the MGuard(TM) Israeli Registry. InspireMD Will Also Sponsor a Satellite Program Breakfast Meeting at the TCT Conference on September 24th 2009 in the Moscone Exhibition Center in San FranciscoSAN FRANCISCO - InspireMD, developers of MGuard(TM), announced today that the first patient has been enrolled in the Israeli MGuard(TM) Registry. MGuard(TM) was successfully implanted in Natanya, Israel, at the Laniado Hospital Cath Lab, managed by Dr. Yitzhak Herz, the principal investigator for the Registry at this hospital. Occlutech Receives Positive Ruling in German Proceeding Initiated by AGA MedicalJENA, Germany - Occlutech GmbH, the leading European developer of products for septal closure, today announced that the district court of Frankfurt, Germany reversed an earlier court injunction obtained by AGA Medical against Occlutech’s sales and marketing activities relating to the newly launched Figulla Flex ranges of ASD and PFO occluders. Abbott’s XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV TrialSAN FRANCISCO - At One Year, XIENCE V Demonstrates: - Statistical Superiority on Primary Endpoint of Target Lesion Failure, with a 38 Percent Reduction Compared to TAXUS Abbott’s XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE TrialSAN FRANCISCO - - Independent Study of 1,800 Patients Affirms Outstanding Performance of XIENCE V vs. TAXUS Liberte Jane Seymour Lends Support to Recognise the Hopes and Achievements of People Living With Rheumatoid Arthritis (RA)MAIDENHEAD, England - - 26 Men and Women With RA From Across Europe Honoured as They Share Their Inspirational Stories Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in Second-Line Metastatic Colorectal CancerTHOUSAND OAKS, California - Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 ‘181′ trial evaluating Vectibix(R) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC. These results were presented at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany (Abstract Number 14LBA). Palonosetron Effectively Prevents Emesis and Nausea Induced by High Dose Chemotherapy in Patients Undergoing Autologous Stem Cell TransplantationBERLIN - - Single Dose Palonosetron Achieves Optimal Control of Acute Emesis in Patients Receiving Multiday-High Dose Chemotherapy Before Autologous Stem Cell Transplantation. New and Interesting PROSTVAC(TM) Data Indicate Broad Therapeutic Use in Metastatic Prostate CancerKVISTGAARD, Denmark - Bavarian Nordic A/S (OMX: BAVA) yesterday presented further detailed PROSTVAC(TM) data at the European Cancer Organisation (ECCO), ECCO 15 - 34th ESMO Congress in Berlin, Germany. Gerresheimer Expands in the Global Pharmaceutical Plastic BusinessDÜSSELDORF, Germany - - Important Investments for Pharmaceutical Markets in the USA and Europe 18th Congress of the European Academy of Dermatology and Venereology October 7-11, 2009 Berlin, GermanyBRUSSELS and BERLIN - - Media Invitation BRUSSELS and BERLIN, September 22 /PRNewswire/ – Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer PatientsTHOUSAND OAKS, California - Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,046 patients with advanced breast cancer that met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa. These results were presented today during the Presidential Session at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany (Abstract Number 2LBA). Agendia Raises US $23 Million in Series E FinancingHUNTINGTON BEACH, California and AMSTERDAM - - Company to Present at UBS Global Life Sciences Conference on Sept. 23 MitraClip(R) Therapy Data Demonstrate Significant Reduction in Mitral Valve Annulus Dimensions in High-Risk Patients With Functional Mitral RegurgitationSAN FRANCISCO - - 12-Month Data Also Demonstrate Significant Reduction in Left Ventricular Volumes Data Show Long-Term Mechanical Integrity of MitraClip(R) and Complete Healing Following Implantation of the Device for Mitral Valve RepairSAN FRANCISCO - - Results of Histopathology and Mechanical Integrity Analysis of MitraClip(R) Devices Presented at TCT 2009 MitraClip(R) Therapy Data Demonstrate Significant Left Ventricular Reverse Remodeling in Patients With Sustained Reduction of Mitral RegurgitationSAN FRANCISCO - - 12-Month Data Presented at TCT 2009 Show Significant Improvement in Left Ventricular Function with no Change in Annular Dimensions More Than 35 Million People Have Alzheimer’s and Dementia Worldwide, According To New ReportNEW YORK - More than 35 million people worldwide will have dementia in 2010, according to the 2009 World Alzheimer’s Report from Alzheimer’s Disease International (ADI). The new report was released on September 21st, which is World Alzheimer’s Day. Zeltiq(TM) Aesthetics Announces European CE Mark Approval for Non-Invasive Fat Layer Reduction Using Cryolipolysis(TM)NICE, France - - Impressive Clinical Results Presented at Major Scientific Meeting of Dermatologists and Plastic Surgeons from Five Continents ASP Launches 24-Minute EXPRESS Cycle for the STERRAD(R) 100NX(TM) SystemIRVINE, California - - New Cycle is One of the Fastest on the Market and is Validated to Sterilize da Vinci(R) 3D Endoscopes Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone MetastasesTHOUSAND OAKS, California - Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3 trial evaluating denosumab administered subcutaneously versus Zometa(R) (zoledronic acid) administered as an intravenous infusion in the treatment of bone metastases in 1,776 advanced cancer patients with solid tumors (not including breast and prostate cancer) or multiple myeloma. These results were presented today at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany (Abstract Number: 20LBA). Simbionix USA Corporation’s Innovative Development Division Releases Two New Breakthrough TechnologiesCLEVELAND, Ohio - Simbionix USA Corporation, the world’s leading developer of medical simulation systems, just released two new products: a new Laparoscopic Essential Tasks Module for its LAP Mentor(TM) and a breakthrough technology for patient-specific simulation based on actual patient data - the PROcedure Rehearsal Studio(TM). Health Robotics Continues Global Expansion Into Oceania With Device Technologies Australia’s Strategic PartnershipBOZEN, Italy - Health Robotics today announced that it has signed an exclusive five-year strategic partnership with Device Technologies Australia Pty Ltd. for its revolutionary CytoCare(TM) Robot. This strategic agreement enables Device Technologies Australia to achieve its goal of safely, accurately and cost-effectively automating the preparation of Oncology I.V. Admixtures to complement its other market-leading Oncology and Surgery Robotic solutions. Leading Cardiovascular Surgeons Gather from Around the World to Share Ross Procedure Survival Data, Techniques at 2nd Annual SummitATLANTA - - Growing Outcomes Evidence Spurs Renewed Interest in Unique Heart Valve Procedure Abbott’s XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III TrialSAN FRANCISCO - - Market-Leading XIENCE V Demonstrates Single-Digit Rate of Major Adverse Cardiac Events (MACE) at Three Years and a 43 Percent Reduction vs. TAXUS Drink-Drive Cambridgeshire Vet Warned as to Future ConductLONDON - Following a two-year postponed judgment, the Disciplinary Committee (DC) of the Royal College of Veterinary Surgeons last week [17 September 2009] warned a Cambridgeshire veterinary surgeon as to his future conduct, after he had been convicted in 2006 for causing death by careless driving whilst under the influence of alcohol. Occlutech and IZASA Obtains Favourable Ruling in Proceeding Initiated by AGA Medical in SpainZURICH - Occlutech AG, the leading European developer of products for septal closure, today announced that, together with its partner in Spain IZASA SA, it defeated a request for an injunction against sales and marketing activities in Spain, launched at the Commercial Court I of Barcelona, Spain by its U.S. competitor AGA Medical. Value of Text Verification Tool (TVT) Strongly Confirmed at RAPS in PhiladelphiaFRANKFURT - Trying economic times mean tight budgets. More projects, fewer people, rigid quality standards and competitve pressures are making the computer-driven proofreading tool made by Schlafender Hase more valuable than ever. NeuroFocus Names Dr. Steven Miller to Head Global Neurological Laboratory OperationsBERKELEY, California - NeuroFocus, the world’s leading neuromarketing company, announced that it has named Dr. Steven L. Miller to lead its neurological testing laboratory facilities. Headquartered in Berkeley, the company operates its main lab there, with additional lab facilities and offices in Cincinnati, Dallas, Israel, Las Vegas, London, Los Angeles, New York, and Asia. |
